The purpose of this study is to see if DNA from cancer tumor cells can be found in cerebral spinal fluid before it is possible to find malignant cancer cells/ Those who enter the trial must have symptoms of leptomeningeal metastases such as headache, vision problems, hearing loss, cognitive loss etc. but can not have had previous central nervous system disease including brain metastases.
This is a phase l study to determine the proper dose and safety of afatinib for women with HER2-positive brain metastases. Afatinib has already been approved for certain types of lung cancer and melanoma. It is an immunotherapeutic drug that keeps cancer cells from shielding themselves from the immune system. There will be groups in the trial each with an escalating dose of afatinib. To enter this trial one previous treatment for brain metastases must have failed, and at least 28 days must have elapsed after whole brain radiation or radiosurgery.
This is a Phase II non-randomized clinical trial to test the safety and efficacy of abemaciclib in hormone receptor positive metastatic breast cancer that is no longer responding to hormonal treatment. Patients can have either Her2+ or Her2- disease. They must have already completed local therapy brain metastases (whole-brain, stereotactic radiation, or surgical removal of brain metastases) and not require any local therapy immediately. Abemaciclib is a CDK 4/6 inhibitor which blocks cancer cell growth and replication.
The purpose of this Phase I study is to find out if capecitabine can be given safely with different doses of lapatinib in patients with HER2-positive breast cancerwith brain metastases. Both drugs have been shown to penetrate the blood-brain barrier and to shrink brain metastases and/or leptomeningeal disease.
The purpose of this French Phase lll study is to compare the progression free survival of leptomeningeal metastasis with the use of intrathecal delivery of liposomal cytarabine, (a chemotherapy drug) versus treatment of physicianâ€™s choice (chemotherapy, hormonal therapy, or targeted therapy) delivered intraveneously (into the veins). Intrathecal delivery of a drug is done by lumber puncture (spinal tap) or through a device placed under the scalp. It infuses the drug directly into the cerebrospinal fluid targeting the cancer cells. Life expectancy must be at least 2 months. Brain metastases are allowed if they are not symptomatic.
This Phase ll study will be looking at whether high-dose methotrexate is effective at controlling leptomeningeal metastasis caused by breast cancer. The methotrexate will be delivered intravenously (into the veins). Patients may also have brain metastases. Everyone in the study receives the treatment.
The purpose of this study is to learn wither the DNA from cancer tumor cells can be found in fluid that surrounds the brain and spinal cord of patients before malignant cells can be found. The researchers hope this information can be used for the earlier diagnosis of leptomeningeal disease. To be included in the trial, patients must have a previously diagnosed solid tumor (outside of the central nervous system) and have signs or symptoms of leptomeningeal disease such as headache, visual problems, hearing loss, cognitive dysfunction, weakness, numbness, cranial neuropathy, bowel or bladder dysfunction, etc. Patients with prior treatment of central nervous system metastases including brain metastases and other CNS metastases are excluded.
In this phase lll trial patients will either receive liposomal cytarabine (chemotherapy) either intravenously (through the veins) or intrathecally (directly into the leptomeninges through a hole in the scalp--See treatment of leptomeningeal disease in this website). Patients can have stable brain metastases but cannot have a mass in the leptomeninges larger than 1 cm. This trial is being done in France.
A French Phase l/ll Trial of Herceptin delivered intrathecally or intraventricularly into the meninges, the fluid surrounding the spinal cord and brain where breast cancer cells can metastasize and form tumors. In intrathecal delivery, the Herceptin is delivered directly into the brain. Intraventricular delivery is directly into the fluid surrounding the spine. For a more detailed description of intrathecal infusion, see the treatments section on leptomeningeal disease. This trial allows women with untreated asymtomatic brain metastases or stable brain metastases after treatment. This dosing and safety study assigns patients to doses starting at 30 mg weekly and going up to 150mg weekly. See the bibliography for case studies that have shown that off label use of this experimental treatment can be effective in some cases, although the proper dose has not yet been established.